Preclinical Development
A novel non-opioid mechanism moves from bench to animal testing.
- 1–3 yrs: Preclinical Duration (target-to-IND timeline)
- 3–5: Animal Pain Models (species tested)
- ~10: IND-Enabling Studies (GLP toxicology studies)
- ~40%: Advance to Phase 1 (preclinical success rate)
Target validation
A pain pathway independent of opioid receptors is confirmed.
Animal pain models
Rodent models test analgesia without opioid-receptor activity.
IND submission
Toxicology data package is filed with the FDA.
Non-opioid mechanisms avoid addiction and respiratory-depression risk.
Phase 1 Trials
Healthy volunteers reveal how the candidate behaves in humans.
- 20–100: Healthy Volunteers (enrolled participants)
- ~1 yr: Trial Duration (safety monitoring window)
- Safety: Primary Endpoint (and pharmacokinetics)
- ~63%: Advance to Phase 2 (Phase 1 success rate)
Dose escalation
Small cohorts test rising doses for tolerability.
Pharmacokinetics
Absorption, metabolism, and clearance rates are measured.
Tolerability screening
Adverse events are tracked before patient trials begin.
No abuse-liability signal appears in early volunteers.
Phase 2/3 Trials
Real pain patients test whether the drug actually works.
- 1,000–3,000: Patient Participants (across combined trials)
- ~3–4 yrs: Trial Duration (efficacy testing window)
- Placebo + opioid: Comparator Arms (active-control design)
- ~30%: Combined Pass Rate (Phase 2/3 success rate)
Phase 2 proof-of-concept
An efficacy signal is confirmed in real pain patients.
Phase 3 confirmation
Large trials confirm efficacy against placebo.
Comparator benchmarking
Pain relief is compared directly against an opioid standard.
Positive Phase 3 data is the single biggest approval driver.
FDA Review
Regulators weigh the entire trial record before a decision.
- ~10 mo: NDA Review Clock (standard review timeline)
- Public vote: Advisory Committee (on benefit-risk balance)
- ~90%: Once NDA Accepted (review success rate)
- ~500,000: Documentation Filed (submission pages)
NDA submission
The full trial dataset is filed for regulatory review.
Advisory committee vote
Independent experts weigh benefit against risk.
Labeling negotiation
Final prescribing information is drafted with regulators.
A non-opioid label carries no controlled-substance scheduling.
Approval & Launch
A decade of work becomes an available non-opioid medicine.
- ~10 yrs: Time to Approval (from preclinical start)
- ~5–10%: Overall Success Rate (candidate to approval)
- Scaled: Launch Readiness (commercial manufacturing)
- Millions: Patients Reached, Yr 1 (projected prescriptions)
FDA approval granted
The first-in-class non-opioid analgesic clears final review.
Commercial launch
Manufacturing and distribution begin nationwide.
Post-market surveillance
Real-world safety is monitored after launch.
A non-addictive option finally reaches chronic pain patients.